Drug Trial Radar · NCT00658528
Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)
Last checked: Nov 20, 2026Latest source record: Dec 21, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,061
Actual
Start
Feb 2008
Primary completion
Sep 2009
Study completion Jan 2010
Sponsor
- Lead sponsor
- Eisai Inc.Eisai
- Sponsor type
- Industry
- First posted
- Apr 15, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the safety and efficacy of Rabeprazole extended release (ER) 50 mg versus Esomeprazole 40 mg for healing and symptomatic relief among subjects with erosive gastroesophageal reflux disease (GERD).
Conditions
- Gastroesophageal Reflux Disease (GERD)
Interventions
Rabeprazole sodiumDrug
Rabeprazole ER 50 mg capsule, taken orally, once daily for 4-8 weeks.
EsomeprazoleDrug
Esomeprazole 40 mg capsule, taken orally, once daily for 4-8 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Erosive Gastroesophageal Reflux Disease (eGERD) Who Achieved Endoscopically-confirmed Healing by 8 WeeksTime frame: Baseline and Week 8
- Percentage of Participants With eGERD Who Achieved Endoscopically-confirmed Healing by 4 WeeksTime frame: Baseline and Week 4
Locations
88 sites in 13 countries. Site status is shown where the registry gives one.
Site not named
Anaheim, California
Site not named
Isidro Casanova, La Matanza, BUE, Argentina
Site not named
Ramos Mejía, BUE, Argentina
Site not named
San Isidro, BUE, Argentina
Site not named
Capital Federal, CBA, Argentina
Site not named
Mendoza, MEN, Argentina
Site not named
Rosario, SFE, Argentina
Site not named
Rosario, SFE, Argentina
Site not named
Rosario, SFE, Argentina
Site not named
San Juan, SJN, Argentina
Site not named
Five Dock, New South Wales, Australia
Site not named
Carina Heights, Queensland, Australia
Site not named
Kippa-Ring, Queensland, Australia
Site not named
Box Hill, Victoria, Australia
Site not named
Frankston, Victoria, Australia
Site not named
Malvern, Victoria, Australia
Site not named
Plovdiv, Bulgaria, Bulgaria
Site not named
Sofia, Bulgaria, Bulgaria
Site not named
Sofia, Bulgaria, Bulgaria
Site not named
Sofia, Bulgaria, Bulgaria
Site not named
Sofia, Bulgaria, Bulgaria
Site not named
Stara Zagora, Bulgaria, Bulgaria
Site not named
Varna, Bulgaria, Bulgaria
Site not named
Saint John, New Brunswick, Canada
Site not named
St. John's, Newfoundland and Labrador, Canada
Site not named
Guelph, Ontario, Canada
Site not named
Hamilton, Ontario, Canada
Site not named
Newmarket, Ontario, Canada
Site not named
Toronto, Ontario, Canada
Site not named
Windsor, Ontario, Canada
Site not named
Montreal, Quebec, Canada
Site not named
Montreal, Quebec, Canada
Site not named
Pointe-Claire, Quebec, Canada
Site not named
Québec, Quebec, Canada
Site not named
Québec, Quebec, Canada
Site not named
Saskatoon, Saskatchewan, Canada
Site not named
Santiago, Chile, Chile
Site not named
Vioa Del Mar, Chile, Chile
Site not named
Rijeka, Croatia, Croatia
Site not named
Zagreb, Croatia, Croatia
Showing 40 of 88 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.